Opko enters into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx). Opko says the purchase agreement is secured by its profit share payments from Pfizer received ...
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. On ...
$OPK insiders have traded $OPK stock on the open market 9 times in the past 6 months. Of those trades, 9 have been purchases and 0 have been sales. Here’s a ...
OPK and PFE received FDA approval for Ngenla in June. This enables OPK to receive royalties going forward. OPK has continued to lose money due to its lab business. The business had sales fall off ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results